Michael Riley - SPDR SP Vice President
| XPH Etf | USD 46.57 0.23 0.50% |
Michael P. Riley is Principle, State Street Global Advisors Assistant Vice President, State Street Bank and Trust Company .
| Age | 43 |
| Tenure | 19 years |
| Issuer | SSgA |
| Inception Date | 2006-06-19 |
| Benchmark | S&P Pharmaceuticals Index |
| Entity Type | Regulated Investment Company |
| Asset Under Management | 164.33 Million |
| Average Trading Valume | 64,354.8 |
| Asset Type | Equity |
| Category | Sector |
| Focus | Health Care |
| Market Concentration | Developed Markets |
SPDR SP Pharmaceuticals Money Managers
| Gary French, Treasurer | ||
| John Clark, Assistant Treasurer | ||
| Dave Kelly, Independent Trustee | ||
| Helen Peters, Independent Trustee | ||
| Matthew Flaherty, Assistant Treasurer | ||
| Michael Riley, Vice President | ||
| Mary Zeven, Secretary | ||
| Chad Hallett, Assistant Treasurer of Street tracks series trust | ||
| Scott Zoltowski, Assistant Secretary | ||
| Peter Ambrosini, Chief Compliance Officer | ||
| James Ross, President Trustee | ||
| Frank Nesvet, Independent Trustee |
SPDR Etf Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right etf is not an easy task. Is SPDR SP a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Price To Earning | 6.56 X | |||
| Price To Book | 1.51 X | |||
| Price To Sales | 2.83 X | |||
| Gross Profit | 2.66 M | |||
| Earnings Per Share | (11.87) X | |||
| Number Of Employees | 12 | |||
| Beta | 0.72 | |||
| Market Capitalization | 236.07 M | |||
| Total Asset | 206.63 M | |||
| One Year Return | 28.70 % |
Currently Active Assets on Macroaxis
When determining whether SPDR SP Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of SPDR SP's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Spdr Sp Pharmaceuticals Etf. Outlined below are crucial reports that will aid in making a well-informed decision on Spdr Sp Pharmaceuticals Etf:Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in SPDR SP Pharmaceuticals. Also, note that the market value of any etf could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
The market value of SPDR SP Pharmaceuticals is measured differently than its book value, which is the value of SPDR that is recorded on the company's balance sheet. Investors also form their own opinion of SPDR SP's value that differs from its market value or its book value, called intrinsic value, which is SPDR SP's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because SPDR SP's market value can be influenced by many factors that don't directly affect SPDR SP's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between SPDR SP's value and its price as these two are different measures arrived at by different means. Investors typically determine if SPDR SP is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, SPDR SP's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.